盐酸厄洛替尼在EGFR突变ⅢB期肺腺癌新辅助治疗的临床研究  

Clinical Study of Erlotinib Hydrochloride in Neoadjuvant Treatment of EGFR-mutant Stage ⅢB Lung Adenocarcinoma

作　　者：陈岸[1] 张继平[1] 陈卫军[1] CHEN An;ZHANG Jiping;CHEN Weijun(Foshan Second People’s Hospital,Foshan 528000,China;不详)

机构地区：[1]佛山市第二人民医院,广东佛山528000

出　　处：《中外医学研究》2020年第34期1-3,共3页CHINESE AND FOREIGN MEDICAL RESEARCH

基　　金：佛山市自筹经费类科技计划项目(2017AB002111)。

摘　　要：目的:分析在表皮生长因子受体(EGFR)突变ⅢB期肺腺癌患者新辅助治疗中应用盐酸厄洛替尼的效果。方法:将2017年10月-2020年4月在笔者所在医院医治的80例EGFR突变ⅢB期肺腺癌患者纳入研究,并随机分为对照组(40例)和试验组(40例),给予对照组实施放疗、胸部调强化疗、中药治疗,给予试验组盐酸厄洛替尼治疗。检测治疗前后肿瘤标志物水平,评价治疗效果和不良反应。结果:治疗后,试验组CEA、CA125水平均低于对照组,差异均有有统计学意义(P<0.05)。试验组治疗总有效率和疾病控制率均高于对照组,差异均有统计学意义(P<0.05)。试验组不良反应发生率低于对照组,差异有统计学意义(P<0.05)。结论:盐酸厄洛替尼应用于EGFR突变ⅢB期肺腺癌患者新辅助治疗中,可有效调节肿瘤标志物水平,具有良好的治疗效果,不良反应较少,值得推广。Objective:To analyze the effect of Erlotinib Hydrochloride in neoadjuvant therapy for patients with epidermal growth factor receptor(EGFR)-mutant stage ⅢB lung adenocarcinoma.Method:A total of 80 patients with EGFR-mutant stage ⅢB lung adenocarcinoma who were treated in our hospital from October 2017 to April 2020 were enrolled in the study,and they were randomly divided into the control group(40 cases)and the experimental group(40 cases),the control group was treated with radiotherapy,intensity-modulated chest chemotherapy and Chinese medicine,the experimental group was treated with Erlotinib Hydrochloride.The levels of tumor markers were detected before and after treatment,and the therapeutic effect and adverse reactions were evaluated.Result:After treatment,the CEA and CA125 levels in the experimental group were lower than those in the control group,the differences were statistically significant(P<0.05).The treatment efficiency and disease control rate in the experimental group were higher than those in the control group,the differences were statistically significant(P<0.05).The incidence of adverse reactions in the experimental group was lower than that in the control group,the difference was statistically significant(P<0.05).Conclusion:Erlotinib Hydrochloride in neoadjuvant treatment of patients with EGFR-mutant stage ⅢB lung adenocarcinoma,can effectively regulate the level of tumor markers,has a good therapeutic effect and has fewer adverse reactions,and is worthy of promotion.

关 键 词：表皮生长因子受体 肺腺癌 盐酸厄洛替尼 

分 类 号：R734.2[医药卫生—肿瘤]